This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AstraZeneca (AZN) Drug Combo Meets Endometrial Cancer Study Goal
by Zacks Equity Research
AstraZeneca (AZN) reports statistically significant results from a late-stage study evaluating the combination of Imfinzi and Lynparza in patients with advanced endometrial cancer.
Apellis' (APLS) Study on Pegcetacoplan to Treat ALS Fails
by Zacks Equity Research
Apellis' (APLS) phase II MERIDIAN study on pegcetacoplan for the treatment of amyotrophic lateral sclerosis fails to meet primary and key secondary endpoints.
Gilead's (GILD) Veklury Gets Positive CHMP View for Extended Use
by Zacks Equity Research
Gilead (GILD) obtains positive opinion for the use of Veklury in COVID-19 patients with severe renal impairment, including those on dialysis, from the European Medicines Agency's CHMP.
INOVIA's (INO) Rare Disease Drug Gets EC's Orphan Tag, Stock Up
by Zacks Equity Research
INOVIA (INO) shares surge 12% in the after-market hours, when its drug for treating a rare respiratory tract disease, INO-3107, receives orphan drug designation from the European Commission.
How Much Upside is Left in Akero Therapeutics, Inc. (AKRO)? Wall Street Analysts Think 29.22%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 29.2% in Akero Therapeutics, Inc. (AKRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Immunovant (IMVT) Q4 Earnings Top Estimates, Pipeline in Focus
by Zacks Equity Research
Immunovant (IMVT) reports narrower-than-expected results in fourth-quarter fiscal 2023. Pipeline development is on track. Stock surges 12% on Monday.
Viking (VKTX) Up 12% as VKTX-2809 Meets Goals in NASH Study
by Zacks Equity Research
A mid-stage study data shows that Viking Therapeutics' (VKTX) VK2809 achieved reductions in liver fat content in patients with biopsy-confirmed NASH, following 12-weeks of treatment.
Here's Why Momentum in Akero Therapeutics, Inc. (AKRO) Should Keep going
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Akero Therapeutics, Inc. (AKRO) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Viatris (VTRS) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Viatris' (VTRS) Q1 results are likely to be impacted by competitive pressure. With the Biocon deal closed, investors await its impact on first-quarter sales.
Why Earnings Season Could Be Great for Akero Therapeutics (AKRO)
by Zacks Equity Research
Akero Therapeutics (AKRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Novo Nordisk (NVO) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Novo Nordisk's (NVO) Diabetes and Obesity Care products are expected to have increased sales in the first quarter of 2023, amid severe competition and pricing pressure in the United States.
Is a Beat on the Cards for Regeneron's (REGN) Q1 Earnings?
by Zacks Equity Research
Regeneron's (REGN) first-quarter earnings are likely to have gotten a boost from the solid performance of Dupixent.
Novavax (NVAX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Novavax (NVAX) is expected to provide updates on its ongoing clinical development in the first quarter of 2023.
Bellerophon (BLPH) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Bellerophon (BLPH) is expected to provide updates on its proprietary INOpulse platform, being developed for treating several pulmonary hypertension indications, on its first-quarter earnings call.
Can Akero Therapeutics, Inc. (AKRO) Climb 42.57% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 42.6% upside potential for Akero Therapeutics, Inc. (AKRO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Madrigal (MDGL) Soars as Resmetirom Meets Goal in NASH Study
by Zacks Equity Research
Madrigal's (MDGL) phase III MAESTRO-NASH study evaluating resmetirom for treating nonalcoholic steatohepatitis and liver fibrosis meets both primary endpoints. Stock rises.
Immunovant's (IMVT) Q2 Earnings In Line, Batoclimab in Focus
by Zacks Equity Research
Immunovant's (IMVT) earnings meet estimates in the fiscal second quarter ending Sep 30, 2022. IMVT deepens focus on developing its lead candidate batoclimab.
Are Medical Stocks Lagging Akero Therapeutics (AKRO) This Year?
by Zacks Equity Research
Here is how Akero Therapeutics, Inc. (AKRO) and AVEO Pharmaceuticals (AVEO) have performed compared to their sector so far this year.
Deciphera's (DCPH) Q3 Loss Narrows, Qinlock Drives Revenues
by Zacks Equity Research
Deciphera (DCPH) reports a narrower-than-expected loss for the third quarter of 2022 while revenues beat estimates. Qinlock drives year-over-year sales.
Editas' (EDIT) Q3 Earnings Beat Estimates, Pipeline in Focus
by Zacks Equity Research
Editas (EDIT) reports a narrower-than-expected loss for the third quarter of 2022. Focus remains on the lead candidate, EDIT-101, as well as other pipeline candidates.
Acadia's (ACAD) Q3 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Acadia (ACAD) reports a narrower-than-expected loss in the third quarter of 2022 while revenues fall shy of estimates. Tightens guidance for Nuplazid.
Horizon's (HZNP) Q3 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Horizon's (HZNP) earnings and revenues beat estimates in the third quarter of 2022. The company raises net sales guidance for 2022. Shares up.
Alkermes (ALKS) Q3 Earnings Meet Estimates, Revenues Miss
by Zacks Equity Research
Alkermes' (ALKS) earnings meet estimates in the third quarter of 2022 while revenues miss the same. The company tightens total revenue guidance for 2022.
Novo Nordisk's (NVO) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Novo Nordisk (NVO) reports better-than-expected Q3 results. Sales are aided by growth in Diabetes and Obesity Care on higher GLP-1 revenues.
Blueprint Medicines (BPMC) Q3 Earnings & Revenues Top Mark
by Zacks Equity Research
Blueprint Medicines' (BPMC) earnings and revenues trump estimates for the third quarter of 2022. The company lowers product revenue guidance for Ayvakit.